^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Anal Carcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Colorectal Cancer)
    New
    Title:

    ONO Receives Approval of Opdivo® (Nivolumab) for Additional Indications of Unresectable Advanced or Recurrent Esophageal Cancer, and MSI-High Unresectable Advanced or Recurrent Colorectal Cancer in Japan for a Partial Change in Approved Items of Manufacturing and Marketing Approval

    Excerpt:
    Ono Pharmaceutical Co., Ltd....and Bristol-Myers Squibb...announced today that ONO received approval of Opdivo® (generic name: nivolumab) Intravenous Infusion (“Opdivo”), a human anti-human programmed cell death-1 (PD-1) monoclonal antibody in Japan for the following two additional indications, for a partial change in approved items of the manufacturing and marketing approval:...Microsatellite instability high (MSI-High) unresectable advanced or recurrent colorectal cancer that has progressed following chemotherapy...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    1062P - Anti-PD1 efficacy in European patients with advanced MSI-H/MMRd non-colorectal cancers

    Published date:
    10/16/2023
    Excerpt:
    Among the 11 patients with rare MSI primary cancer (pancreas, breast, anal, GU), the overall ORR was 36% (4 patients)….This study confirms the anti-PD1 nivolumab efficacy in non-colorectal MSI patients, even in rare MSI tumours of European patients.